FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282968322> ?p ?o ?g. }

• W4282968322 endingPage "4234" @default.
• W4282968322 startingPage "4224" @default.
• W4282968322 abstract "The reduced cost of trastuzumab biosimilars has led to increased adoption for HER2-positive breast cancer. This review of trastuzumab biosimilars encompasses this development and real world clinical data in early breast cancer. In addition, we present a retrospective study evaluating the total pathological complete response (tpCR) rates (lack of residual invasive cancer in resected breast tissue and axillary nodes), of MYL-1401O to reference trastuzumab (TRZ) in the neoadjuvant setting for HER2+ early breast cancer (EBC) in Alberta, Canada. Neoadjuvant patients with HER2+ EBC treated with TRZ from November 2018–October 2019 and MYL-1401O from December 2019–September 2020 were identified. Logistic regression was used to control for variables potentially associated with tpCR: trastuzumab product, age, pre-operative T- and N-stage, grade, hormone receptor (HR)-status, HER2-status, chemotherapy regimen, and chemotherapy completion. tpCR was 35.6% in the MYL-1401O group (n = 59) and 40.3% in the TRZ (n = 77) group, p = 0.598. After controlling for clinically relevant variables, there was no significant difference in the odds of achieving tpCR in patients treated with TRZ versus MYL-1401O (OR 1.1, 95% CI 0.5–2.4, p = 0.850). tpCR rates were similar for patients treated with MYL-1401O compared to trastuzumab in our real world study of HER2+ neoadjuvant EBC and comparable to pivotal phase 3 trials." @default.
• W4282968322 created "2022-06-17" @default.
• W4282968322 creator A5021077843 @default.
• W4282968322 creator A5023283384 @default.
• W4282968322 creator A5034112415 @default.
• W4282968322 creator A5056756378 @default.
• W4282968322 creator A5085112462 @default.
• W4282968322 creator A5087096775 @default.
• W4282968322 date "2022-06-11" @default.
• W4282968322 modified "2023-10-10" @default.
• W4282968322 title "A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab" @default.
• W4282968322 cites W1577058243 @default.
• W4282968322 cites W1824753370 @default.
• W4282968322 cites W2015960413 @default.
• W4282968322 cites W2043070875 @default.
• W4282968322 cites W2079491290 @default.
• W4282968322 cites W2095861620 @default.
• W4282968322 cites W2098775844 @default.
• W4282968322 cites W2117984780 @default.
• W4282968322 cites W2123591186 @default.
• W4282968322 cites W2137228442 @default.
• W4282968322 cites W2143967622 @default.
• W4282968322 cites W2279656465 @default.
• W4282968322 cites W2292154624 @default.
• W4282968322 cites W2318605753 @default.
• W4282968322 cites W2379981061 @default.
• W4282968322 cites W2509046259 @default.
• W4282968322 cites W2530584466 @default.
• W4282968322 cites W2560234483 @default.
• W4282968322 cites W2560406314 @default.
• W4282968322 cites W2620735862 @default.
• W4282968322 cites W2785217251 @default.
• W4282968322 cites W2793844821 @default.
• W4282968322 cites W2806386505 @default.
• W4282968322 cites W2809293192 @default.
• W4282968322 cites W2820616462 @default.
• W4282968322 cites W2899659781 @default.
• W4282968322 cites W2904249805 @default.
• W4282968322 cites W2949358313 @default.
• W4282968322 cites W2982154937 @default.
• W4282968322 cites W3080572958 @default.
• W4282968322 cites W3081665155 @default.
• W4282968322 cites W3090605047 @default.
• W4282968322 cites W3095756671 @default.
• W4282968322 cites W3129114777 @default.
• W4282968322 cites W3149458367 @default.
• W4282968322 cites W3166492122 @default.
• W4282968322 cites W3169076687 @default.
• W4282968322 cites W3194996474 @default.
• W4282968322 cites W4214911158 @default.
• W4282968322 cites W4220908341 @default.
• W4282968322 doi "https://doi.org/10.3390/curroncol29060337" @default.
• W4282968322 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35735446" @default.
• W4282968322 hasPublicationYear "2022" @default.
• W4282968322 type Work @default.
• W4282968322 citedByCount "1" @default.
• W4282968322 crossrefType "journal-article" @default.
• W4282968322 hasAuthorship W4282968322A5021077843 @default.
• W4282968322 hasAuthorship W4282968322A5023283384 @default.
• W4282968322 hasAuthorship W4282968322A5034112415 @default.
• W4282968322 hasAuthorship W4282968322A5056756378 @default.
• W4282968322 hasAuthorship W4282968322A5085112462 @default.
• W4282968322 hasAuthorship W4282968322A5087096775 @default.
• W4282968322 hasBestOaLocation W42829683221 @default.
• W4282968322 hasConcept C121608353 @default.
• W4282968322 hasConcept C126322002 @default.
• W4282968322 hasConcept C143998085 @default.
• W4282968322 hasConcept C146357865 @default.
• W4282968322 hasConcept C151730666 @default.
• W4282968322 hasConcept C2776694085 @default.
• W4282968322 hasConcept C2779786085 @default.
• W4282968322 hasConcept C2781413609 @default.
• W4282968322 hasConcept C530470458 @default.
• W4282968322 hasConcept C59491497 @default.
• W4282968322 hasConcept C71924100 @default.
• W4282968322 hasConcept C86803240 @default.
• W4282968322 hasConceptScore W4282968322C121608353 @default.
• W4282968322 hasConceptScore W4282968322C126322002 @default.
• W4282968322 hasConceptScore W4282968322C143998085 @default.
• W4282968322 hasConceptScore W4282968322C146357865 @default.
• W4282968322 hasConceptScore W4282968322C151730666 @default.
• W4282968322 hasConceptScore W4282968322C2776694085 @default.
• W4282968322 hasConceptScore W4282968322C2779786085 @default.
• W4282968322 hasConceptScore W4282968322C2781413609 @default.
• W4282968322 hasConceptScore W4282968322C530470458 @default.
• W4282968322 hasConceptScore W4282968322C59491497 @default.
• W4282968322 hasConceptScore W4282968322C71924100 @default.
• W4282968322 hasConceptScore W4282968322C86803240 @default.
• W4282968322 hasIssue "6" @default.
• W4282968322 hasLocation W42829683221 @default.
• W4282968322 hasLocation W42829683222 @default.
• W4282968322 hasLocation W42829683223 @default.
• W4282968322 hasOpenAccess W4282968322 @default.
• W4282968322 hasPrimaryLocation W42829683221 @default.
• W4282968322 hasRelatedWork W1722328147 @default.
• W4282968322 hasRelatedWork W2388730008 @default.
• W4282968322 hasRelatedWork W2794649617 @default.
• W4282968322 hasRelatedWork W2794755138 @default.

• next